Our Recent Posts

Tags

No tags yet.

Improvements in Irritability w/ Concerta in Youth with Comorbid ADHD and DMDD

Drew E Winters, Sadaaki Fukui, Ellen Leibenluft, Leslie A Hulvershorn

Journal of Child and Adolescent Psychopharmacology 2018, 28 (5): 298-305

OBJECTIVE: The purpose of this open-label study was to examine the effects of long-acting methylphenidate (MPH) treatment on irritability and related emotional symptoms associated with disruptive mood dysregulation disorder (DMDD) in youth with comorbid attention-deficit/hyperactivity disorder (ADHD).

METHODS: The sample included 22 medication-free male and female subjects (ages 9-15) who met criteria for both DMDD and ADHD. Participants underwent a 4-week trial of long-acting MPH treatment (Concerta® ), with weekly dosing increases until a therapeutic dose was reached. Repeated measures t-tests were used to compare pre- and posttreatment ratings of primary and secondary measures. The primary outcome was self-report irritability. Secondary outcomes included parent and child ratings of emotional frequency, emotional lability, and negative affect (NA). Multiple regression was used to examine the impact baseline hyperactivity, age, gender, race, socioeconomic status, or comorbid diagnosis had on treatment outcomes.

RESULTS: Significant improvements (medium to large effect sizes) in child-rated irritability as well as parent and child ratings of emotional lability, NA, and anger were found. As anticipated, ADHD symptoms also improved. While a majority of the sample saw improvement in child-rated irritability (71%), symptoms worsened a small proportion (19%), and an even smaller portion experienced no change (10%). No demographics, psychiatric comorbidities, or severity of ADHD symptoms influenced treatment outcomes.

CONCLUSIONS: Study findings suggest that MPH treatment significantly improved mood and emotional symptoms associated with DMDD comorbid with ADHD. These findings, coupled with good tolerability in this open-label pilot study supports further research into the use of MPH as a first-line treatment for DMDD. Future work examining MPH treatment of youth with DMDD with and without comorbid ADHD is needed.

 

You may use Zelle (Chase QuickPay) for payment, linked to 917-621-6615 or mark@markwwilsonmdpc.com

Alternatively, you may use PayPal or give my assistant credit card information or send payment by check.

mark@markwwilsonmdpc.com

assistant@markwwilsonmdpc.com

office (917) 441-2344

emergency (917) 347-8521

©2018 by Mark W. Wilson, MD, PC. Proudly created with Wix.com